Comprehensive CRO Services: BA/BE, Clinical Trials, NG Tube, Adhesion, Skin-Irritation & Sensitization Studies
In-Vitro Permeation Testing (IVPT) and In-Vitro Release Testing (IVRT) Studies
In an increasingly complex and volatile global healthcare environment, commercial success demands absolute precision in clinical execution, bioequivalence modeling, and regulatory compliance. At PharpleQ Lifesciences, we operate as a premier, asset-light Contract Research Organization (CRO). We bridge the gap between advanced formulation design and global regulatory market approvals.Backed by the PharpleQ technical team's vast experience working in top-tier CRO environments, we combine decades of deep scientific knowledge, operational mastery, and trial oversight. Our operations are centered at world-class facilities carrying the industry’s most stringent global regulatory credentials: US-FDA, EMA, WHO-GCP/GLP, UK-MHRA, ANVISA, TGA, GCC and local CDSCO/DCGI clearances.
CRO selection, Scientific Study Design, Protocol Development, & Medical Writing
A successful clinical trial or bioequivalence study is won or lost in the design phase. Leverage the PharpleQ's extensive CRO lineage to ensure your study protocols withstand rigorous regulatory scrutiny and prevent downstream amendments.
Customized Study Design Engineering
We specialize in the conceptualization and structuring of scientifically sound clinical designs tailored to the molecule's specific biopharmaceutical properties, including:
- Randomized, Two-Way / Four-Way Replicated Crossover Designs (critical for highly variable drugs).
- Parallel Study Designs for molecules with ultra-long elimination half-lives.
- Fasted vs. Fed Food-Effect Challenge Studies strictly aligned with FDA, EMA, and ICH guidelines.
Comprehensive Protocol Authoring
- Compilation of the Clinical Trial Protocol, which acts as the operational and scientific backbone of the study. We author clear boundaries for inclusion/exclusion criteria, safety markers, explicit wash-out periods, and precise dosing regimens.
Core Document Construction
- Drafting of complete, audit-proof documents, Informed Consent Form Documents (ICF) available in multiple regional languages, and customized Electronic Case Report Forms (eCRF) built to eliminate data collection ambiguity.
Advanced Bioequivalence (BA/BE) & Biopharmaceutics Services
We execute highly controlled Bioavailability (BA) and Bioequivalence (BE) studies designed to demonstrate therapeutic equivalence for generic filings and lifecycle modifications across international jurisdictions.
Healthy Volunteer & Patient Clinical Unit (CRU) Infrastructure.
Demographically Screened Panels
- Access to fully genotyped volunteer databases to control for metabolic variations (e.g., CYP2D6/CYP2C19 fast/slow metabolizers).
Environmentally Monitored In-House Clinics
- Specialized Phase I/II clinical pharmacology units equipped with synchronized automated blood collection configurations and continuous telemetry monitoring.
Bioanalytical Execution (GLP Liquid Chromatography-Mass Spectrometry)
High-Throughput Ultra-Trace Extraction
- Automated sample preparation (solid-phase extraction [SPE], liquid-liquid extraction) to isolate analytes from complex biological matrices.
LC-MS/MS Selectivity
- Validation of ultra-sensitive assays per ICH M10 bioanalytical guidelines, reaching parts-per-trillion (pg/mL) lower limits of quantification (LLOQ) with strict matrix effect overrides.
Pharmacokinetic (PK) Modeling, Biostatistics, & Report Evaluation
The biostatistics and pharmacometrics division translates raw bioanalytical concentration numbers into definitive, regulatory-compliant data frameworks.
Advanced Pharmacokinetic (PK) Data Extraction & Modeling
Non-Compartmental Analysis (NCA)
Accurate determination of definitive PK parameters utilizing fully validated Phoenix WinNonlin software architecture, mapping:
- Cmax: Peak maximum systemic drug concentration.
- AUC0-t and AUC0-inf: Area under the plasma concentration-time curve, representing total drug exposure.
- Tmax: Precise time point required to reach maximum systemic absorption.
- lambda z and t1/2: Elimination rate constant and terminal half-life metrics.
Compartmental Modeling & Compartmental PK/PD Linkage
- Deeper mathematical evaluation of drug distribution volumes and clearance profiles to support complex generic variations or initial Phase I ascending dose data sets.
Strict Biostatistical Testing & SAS Processing
ANOVA & Power Calculations
- Processing of log-transformed PK parameters using validated SAS software. We calculate analysis of variance (ANOVA) parameters to isolate variations stemming from treatment effects, periods, sequences, and subjects.
Regulatory 90% Confidence Interval (CI) Validation
- Calculation of the geometric mean ratios (Test/Reference). The 90% CI for Cmax and AUC must fall strictly within the 80.00% – 125.00% regulatory boundary window to authorize bioequivalence sign-off.
Integrated Report Evaluation & CSR Compilation
ICH E3-Compliant Clinical Study Reports (CSR)
- We evaluate and compile the final, comprehensive CSR. This structured technical narrative synthesizes the clinical execution log, bioanalytical validations, PK parameters, and biostatistical matrices into a clean, submission-ready electronic module.
Definitive Clinical Interpretation
- Expert medical and scientific summaries outlining the safety profile, tolerability results, and pharmacokinetic compliance of the formulation.
Specialized Dosage Form Studies & Complex Modalities
We possess the technical leadership to design and execute niche biopharmaceutics studies for high-barrier dosage forms, critical patient populations, and narrow therapeutic index matrices.
Oncology Formulations & Nasogastric (NG) Tube In-Vitro / In-Vivo Studies
In-Vitro Tube Recovery & Dispersion Dynamics
- For critical oncology therapeutics administered via enteral routes, we evaluate dispersion recovery percentages, sedimentation profiles, and chemical stability across variable tube materials (polyurethane, silicone, PVC) and bore sizes under varying pH streams (water, juice, apple sauce).
In-Vivo Pharmacokinetic Bio-Validation
- Execution of cross-over clinical trials in designated clinical units to monitor systemic absorption equivalence when administered traditionally vs. flushed via feeding tubes, ensuring patient safety and drug delivery consistency.
Transdermal & Topical Delivery Systems (TDS)
In-Vivo Adhesion Scaling
- Quantitative evaluation of transdermal patch adhesion profiles over specified wear periods (e.g., 24 to 168 hours) using customized, FDA-aligned scoring scales.
Skin Irritation & Sensitization Profiling
- Formalized testing designs in healthy volunteers to map dermatological scoring indexes, checking local tolerance profiles under single and cumulative patch application protocols.
In-Vitro Permeation (IVPT) & In-Vitro Release Testing (IVRT)
IVRT (Release Kinetics)
- Deployment of automated Vertical Diffusion Cells (Franz Cells) utilizing qualified synthetic or biomimetic membranes to quantify release flux rates (mg/cm^2/hr^0.5) for topical creams, ointments, and gels per FDA unit-dose guidance.
IVPT (Skin Permeation Profiles)
- Ex-vivo human cadaver skin matrices configured on temperature-regulated diffusion arrays to accurately chart real-time systemic absorption velocities, frequently acting as a surrogate for clinical endpoints.
Comprehensive Clinical Trial Management (Phase I – IV)
From first-in-human trials through post-marketing safety surveillance, we handle clinical execution under uncompromising adherence to ICH-E6(R2/R3) Good Clinical Practice (GCP) mandates.
Phase I: Clinical Pharmacology (SAD/MAD)
- Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) designs to map safe human exposure thresholds and pharmacokinetic linearity windows.
Phase II: Therapeutic Exploratory / Proof-of-Concept
- Evaluation of initial efficacy profiles and biomodal dose-ranging models in targeted patient cohorts.
Phase III: Confirmatory Pivotal Multi-Center Studies
- Large-scale, randomized, double-blind, active or placebo-controlled trials across multi-country investigational sites to lock down statistical non-inferiority or superiority data portfolios.
Phase IV: Post-Marketing Surveillance
- Real-World Evidence (RWE) accumulation and proactive drug safety registries to track long-term safety profiles across diverse populations.
End-to-End Operational Governance & Activity Streamlining
We streamline all operational interventions through a strict, high-velocity project management framework to keep your trial running on time and on budget.
Study Initialization & Kick-off Matrix
- Complete alignment of cross-functional teams, charting key project dependencies, communication trees, and escalation path protocols.
Global Site Feasibility & Investigator Selection
- Objective data audits across an established global network of hospitals and clinical sites to assess historical recruitment performance, facility capability, and investigator qualifications.
Regulatory Clearances & Bioethics Approvals
- Streamlined management of parallel submissions to national regulatory boards (e.g., FDA IND/NDA, CDSCO, EMA) and Institutional Review Boards (IRB) / Independent Ethics Committees (IEC).
Active Clinical Monitoring & Site Oversight
- Constant on-site and remote monitoring visits by qualified Clinical Research Associates (CRAs) to execute 100% Source Data Verification (SDV) and ensure clinical site compliance.
Clinical Data Management Systems (CDMS)
- Deployment of fully validated Electronic Data Capture (EDC) systems operating under 21 CFR Part 11 protocols, utilizing automated edit checks, query tracking loops, and MedDRA/WHO-Drug coding.
Third-Party External Monitoring & Independent Auditing
To ensure absolute neutrality, minimize sponsor liability, and enforce uncompromising compliance data streams, we integrate an independent, ring-fenced Third-Party External Quality Assurance & Monitoring loop into our operational models.
Independent Co-Monitoring & For-Cause Audits
- Independent external auditors execute unannounced on-site co-monitoring visits alongside our project CRAs. This process provides an unbiased evaluation of site compliance, subject safety protocols, and source-document fidelity.
GCP/GLP Facility Auditing
- Continuous external verification of bioanalytical mass-spectrometry laboratories and clinical trial sites. This includes auditing computerized system access logs, calibration logs, and physical sample chain-of-custody freezers (-70°C validation metrics).
Blinded Data Verification & Random Verification Loops
- Independent data verification experts perform random sampling of raw clinical report forms against raw hospital medical histories, checking that zero transcriptional errors or unauthorized protocol alterations pass into the master lock database.
Clinical, Bioanalytcal, Pharmacokinetic & Biostatistical Deliverables
At the completion of the operational lifecycle, PharpleQ hands over a comprehensive, fully eCTD package of technical data and documents designed for direct integration into international regulatory dossiers.
Clinical Data Modules
- Final Clinical Trial Protocol & Amendments: The definitive authorized historical scientific blueprint of the study.
- Signed eCRF and Informed Consent Portfolios: Complete, anonymized, fully documented trial enrollment validation trail.
- Investigator Documentation Records: Medical licenses, CVs, and site financial disclosure declarations ready for regulatory archiving.
Bioanalytical & Validation Data Modules
- Bioanalytical Method Validation Report (BMVR): Detailed documentation proving assay linearity, selectivity, accuracy, precision, stability, and matrix limits per ICH M10 rules.
- Raw Chromatographic and Injection Sequence Files: Unedited injection logs, baseline integrations, and calibration curve parameters matching biological plasma samples.
Pharmacokinetic & Biostatistical Deliverables
- CDISC-Compliant Datasets: Fully validated SDTM and ADaM data matrices generated via SAS software, formatted for direct upload to electronic regulatory gates.
- Statistical Analysis Plan (SAP) & SAS Output Files: Complete breakdown of the raw numerical runs, power calculations, ANOVA summaries, and 90% Confidence Interval validation curves.
- ICH E3-Compliant Clinical Study Report (CSR): The definitive, OCR, audit-ready technical report summarizing the absolute safety, tolerability, and pharmacokinetic profiles required for global market authorization applications.